Lytix Biopharma AS (id:10507 LYTIX)
5.96 NOK
Opening hours: 09:00 - 16:20 (Central European Standard Time: 12/24/2024 5:44:01 PM)
Exchange closed, opens in 15 hours 15 minutes
3.11 NOK (3.11%)
3.00 NOK (3.00%)
-12.35 NOK (-12.35%)
-35.91 NOK (-35.91%)
25.74 NOK (25.74%)
-72.28 NOK (-72.28%)
About Lytix Biopharma AS
Market Capitalization 372.08M
Lytix Biopharma ASA, a clinical stage biotech company, develops novel cancer immunotherapies for cancer therapy in Norway. Its lead product candidate is LTX-315, an oncolytic molecule that is developed for intratumoral injections, is designed for the local treatment of solid tumors that is in Phase II clinical trials. The company's products comprise of LTX-401, an oncolytic molecule for targeting deep-seated lesions, such as liver cancer and is in a preclinical phase. Lytix Biopharma ASA was incorporated in 2003 and is based in Oslo, Norway.
| Headquarters (address) |
Sandakerveien 138 Oslo 0484 Norway |
| Phone | |
| Website | https://www.lytixbiopharma.com |
| Employees | 0 |
| Sector | Healthcare |
| Industry | Biotechnology |
| Ticker | LYTIX |
| Exchange | Oslo Stock Exchange |
| Currency | NOK |
| 52 week range | 4.62 - 15.00 |
| Market Capitalization | 372.08M |
| P/E trailing | -2.67 |
| P/E forward | -1.60 |
| Price/Sale | 25.76 |
| Price/Book | 5.85 |
| Beta | 3.00 |
| EPS | -1.72 |
| EPS Norway (ID:238, base:161) | 8.25 |